Biotechnology

As the biotechnology sector matures and brings products to market, it is rapidly evolving and restructuring in response to unique challenges and opportunities.  Driven by the forces of competition, pricing pressure and funding challenges, the biotech sector is moving on multiple fronts – locating activities around the world and expanding aggressively into new industries and products.  In this environment, companies need to find ways to increase the efficiency and productivity of drug development – simply, they need to do more with less and do it faster.

Our professionals have the technical and industry knowledge to efficiently negoitiate development stage and biotechnology specific issues. Industry specific issues include:

• Revenue recognition and sales allowance;
• Pre-launch inventory;
• In-process research and development;
• Research and collaboration arrangements;
• Patents and other intangible assets;
• Development stage reporting;
• Complex debt and equity arrangements; and
• Share-based compensation.

The biotechnology sector faces some of the most rigorous challenges new businesses can encounter including substantial regulatory hurdles during product development. At the same time bio-entrepreneurs are developing their core business, they must also navigate the complex financing and reporting environment necessary to operate as a publicly-traded company. As a PCAOB registered accounting firm focused on emerging companies in the public markets, we assist our clients through the development stage accounting issues particular to the life sciences industries. We bring our SEC reporting experience to our clients as they consider initial public offerings, registration statements, reverse mergers and other business combinations.